» Articles » PMID: 31190075

Sepsis in the Era of Data-driven Medicine: Personalizing Risks, Diagnoses, Treatments and Prognoses

Abstract

Sepsis is a series of clinical syndromes caused by the immunological response to infection. The clinical evidence for sepsis could typically attribute to bacterial infection or bacterial endotoxins, but infections due to viruses, fungi or parasites could also lead to sepsis. Regardless of the etiology, rapid clinical deterioration, prolonged stay in intensive care units and high risk for mortality correlate with the incidence of sepsis. Despite its prevalence and morbidity, improvement in sepsis outcomes has remained limited. In this comprehensive review, we summarize the current landscape of risk estimation, diagnosis, treatment and prognosis strategies in the setting of sepsis and discuss future challenges. We argue that the advent of modern technologies such as in-depth molecular profiling, biomedical big data and machine intelligence methods will augment the treatment and prevention of sepsis. The volume, variety, veracity and velocity of heterogeneous data generated as part of healthcare delivery and recent advances in biotechnology-driven therapeutics and companion diagnostics may provide a new wave of approaches to identify the most at-risk sepsis patients and reduce the symptom burden in patients within shorter turnaround times. Developing novel therapies by leveraging modern drug discovery strategies including computational drug repositioning, cell and gene-therapy, clustered regularly interspaced short palindromic repeats -based genetic editing systems, immunotherapy, microbiome restoration, nanomaterial-based therapy and phage therapy may help to develop treatments to target sepsis. We also provide empirical evidence for potential new sepsis targets including FER and STARD3NL. Implementing data-driven methods that use real-time collection and analysis of clinical variables to trace, track and treat sepsis-related adverse outcomes will be key. Understanding the root and route of sepsis and its comorbid conditions that complicate treatment outcomes and lead to organ dysfunction may help to facilitate identification of most at-risk patients and prevent further deterioration. To conclude, leveraging the advances in precision medicine, biomedical data science and translational bioinformatics approaches may help to develop better strategies to diagnose and treat sepsis in the next decade.

Citing Articles

Identification of prognostic biomarkers of sepsis and construction of ceRNA regulatory networks.

Chen G, Zhang W, Wang C, Chen M, Hu Y, Wang Z Sci Rep. 2025; 15(1):2850.

PMID: 39843498 PMC: 11754875. DOI: 10.1038/s41598-024-78502-3.


Screening of prognostic core genes based on cell-cell interaction in the peripheral blood of patients with sepsis.

Li S, Chen W, Zhang Z, Yuan L, Hu Y, Chen M Open Life Sci. 2024; 19(1):20220999.

PMID: 39655195 PMC: 11627055. DOI: 10.1515/biol-2022-0999.


Role of Cellular Senescence Genes and Immune Infiltration in Sepsis and Sepsis-Induced ARDS Based on Bioinformatics Analysis.

Wu X, Guo Y J Inflamm Res. 2024; 17:9119-9133.

PMID: 39588141 PMC: 11586271. DOI: 10.2147/JIR.S488463.


Correlation of serum H-FABP, sTREM-1, and HMGB1 levels with severity and prognosis of sepsis.

Jiang S, Liu L, Zhu X Am J Transl Res. 2024; 16(10):5846-5855.

PMID: 39544769 PMC: 11558379. DOI: 10.62347/KELZ4296.


Screening and Application of DNA Aptamers for Heparin-Binding Protein.

Zhou X, Cao Y, Huang X, Qiu S, Xiang X, Niu H Molecules. 2024; 29(8).

PMID: 38675537 PMC: 11051826. DOI: 10.3390/molecules29081717.


References
1.
Kullberg B . Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis. 1997; 16(1):51-5. DOI: 10.1007/BF01575121. View

2.
Spence S, Greene M, Fay F, Hams E, Saunders S, Hamid U . Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med. 2015; 7(303):303ra140. DOI: 10.1126/scitranslmed.aab3459. View

3.
Rautanen A, Mills T, Gordon A, Hutton P, Steffens M, Nuamah R . Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2014; 3(1):53-60. PMC: 4314768. DOI: 10.1016/S2213-2600(14)70290-5. View

4.
Denny J, Bastarache L, Ritchie M, Carroll R, Zink R, Mosley J . Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013; 31(12):1102-10. PMC: 3969265. DOI: 10.1038/nbt.2749. View

5.
Dickson R, Singer B, Newstead M, Falkowski N, Erb-Downward J, Standiford T . Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016; 1(10):16113. PMC: 5076472. DOI: 10.1038/nmicrobiol.2016.113. View